Offsets deal reached to fund US FDA, NIH 'Cures' bill
This article was originally published in SRA
Executive Summary
Republican and Democratic leaders of the US House energy and commerce committee late on 20 May said they had reached a deal on how they will pay for the expected $13bn costs of implementing the provisions in the proposed 21st Century Cures Act (HR 6). The bill is aimed at overhauling the US biomedical enterprise, and is intended to speed up the discovery, development and approval processes for therapies, devices and diagnostics1.